Paper Details

  1. Home
  2. Paper Details

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.

Author: BauknechtT, CostaS, EmonG, JackischC, LückH J, MeierW, MoebusV, OlbrichtS, RichterB, SchroederW, WagnerU, duBois A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

While most ovarian cancer patients don't achieve a cure with initial treatments, current second-line chemotherapy options haven't shown significant benefits and often cause side effects. This study explores whether a less toxic hormonal treatment might be a better option for these patients compared to chemotherapy.
Paper Details　
Original Abstract of the Article :
The majority of patients with ovarian cancer are not cured by first-line treatment. Until now, no study could demonstrate any substantial benefit when exposing ovarian cancer patients to second-line chemotherapy. However, most treatment regimens induce toxicity, thus negatively influencing the quali...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11886002

データ提供：米国国立医学図書館（NLM）

Ovarian Cancer: A Journey Through the Desert of Treatment Options

This research explores the challenging landscape of ovarian cancer treatment, examining the effectiveness of chemotherapy versus hormonal therapy in patients with platinum- and paclitaxel-refractory disease. The authors conducted a randomized trial to compare the outcomes of these two treatment approaches.

Navigating the Desert of Treatment Alternatives

The study found that second-line chemotherapy did not offer a significant benefit compared to hormonal treatment, highlighting the need for further research into more effective therapies for this challenging condition.

Dr. Camel's Conclusion

This research highlights the complexities of treating ovarian cancer, emphasizing the need for individualized treatment approaches and continued exploration of new therapies. It serves as a reminder that navigating the desert of cancer treatment requires ongoing research and innovation to improve outcomes for patients.

Date :
  1. Date Completed 2002-08-22
  2. Date Revised 2020-02-03
Further Info :

Pubmed ID

11886002

DOI: Digital Object Identifier

S0923-7534(19)62809-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.